Sera Prognostics to Present at 33rd Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, December 23, 2014–Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the 33rd annual J.P. Morgan Healthcare Conference. Dr. Critchfield’s presentation will take place at 4:30 p.m. PT on Wednesday, January 14, 2015 at the Westin St. Francis Hotel in San Francisco, CA.

About Sera Prognostics, Inc.

Sera Prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth and other pregnancy complications. Sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. The company has assembled a strong management team and Board of Directors with significant clinical development and women’s healthcare diagnostic experience. Sera’s Proteomic Assessment of Preterm Birth study is fully enrolled, as one of the world’s largest and broadest clinical trials to validate the performance of the Company’s PreTRMTM Test for predicting the risk of preterm birth. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

About Sera Prognostics, Inc.

Sera Prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. Sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. The company has assembled a strong management team and Board of Directors with significant clinical development and women’s healthcare diagnostic experience. Sera has conducted the Proteomic Assessment of Preterm Risk (PAPR) study, one of the world’s largest and broadest clinical trials to validate the performance of the Company’s PreTRM™ test. PAPR enrolled 5,501 patients from 11 centers across the United States, representing the diversity of the intended use population for asymptomatic singleton pregnancies. The Company is supported by a strong group of investors, including Chione, Ltd, Domain Associates, InterWest Partners, Catalyst Health Ventures, UpStart Life Sciences Capital, and Osage University Partners. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

Company Contact:                                                   
Andrew Sauter, CFO                                                    
Sera Prognostics, Inc.                                                  
info@seraprognostics.com
(801) 990-0772                                                             
 
MediaContact for Sera Prognostics:
Terri Clevenger
Continuum Health Communications
tclevenger@continuumhealthcom.com
(203) 856-4326